Sopharma AD Second Quarter 2024 Earnings: EPS: лв0.081 (vs лв0.26 in 2Q 2023)
Sopharma AD (BUL:SFA) Second Quarter 2024 Results
Key Financial Results
- Revenue: лв495.1m (up 9.3% from 2Q 2023).
- Net income: лв16.1m (down 48% from 2Q 2023).
- Profit margin: 3.3% (down from 6.9% in 2Q 2023). The decrease in margin was driven by higher expenses.
- EPS: лв0.081 (down from лв0.26 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sopharma AD shares are up 1.4% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Sopharma AD (1 is a bit unpleasant!) that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUL:SFA
Sopharma AD
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.
Excellent balance sheet second-rate dividend payer.
